MARKET

CVAC

CVAC

CureVac B.V.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

82.10
-2.96
-3.48%
After Hours: 80.00 -2.1 -2.56% 18:16 11/24 EST
OPEN
82.38
PREV CLOSE
85.06
HIGH
84.95
LOW
76.29
VOLUME
631.21K
TURNOVER
--
52 WEEK HIGH
85.68
52 WEEK LOW
36.15
MARKET CAP
14.49B
P/E (TTM)
-141.4542
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
EU strikes deal with Moderna to supply up to 160 million vaccine shots
The European Union has now negotiated six supply deals with vaccine makers to secure COVID-19 shots.
MarketWatch · 15h ago
Pfizer/BioNTech to seek emergency authorization of Covid-19 vaccine Friday
MarketWatch · 4d ago
BioNtech and Moderna Vaccines May Get Emergency Use Approval In Europe
In an attempt to “synchronize” COVID-19 vaccine distribution at par with the U.S., the European Union is deliberating the idea of granting  Pfizer Inc (NYSE: PFE)-BioNTech SE (NASDAQ: 
Benzinga · 4d ago
EU may approve BioNtech, Moderna vaccines in December, could pay $10B for doses
According to the head of European Commission ((EC)), Pfizer (PFE), BioNTech (BNTX) and Moderna (MRNA) could receive conditional European Union ((EU)) marketing authorization for their COVID-19 vaccines in the second
Seekingalpha · 4d ago
Maravai IPO: What Investors Should Know About Pfizer/BioNTech COVID-19 Vaccine Partner
Maravai Life Sciences Holdings (NASDAQ:MRVI) will hit the public markets with perfect timing as it sees its mRNA product used by COVID-19 vaccine makers.
Benzinga · 5d ago
CureVac to ramp up COVID vaccine capacity to 300M doses
CureVac (CVAC) says it is building a network with partners to increase manufacturing capacity of its COVID-19 vaccine candidate CVnCoV to as much as 300M doses in 2021 and 600M
Seekingalpha · 11/17 14:21
CVS Health, Walgreens Boots Alliance among major healthcare premarket losers' pack
Brainstorm Cell Therapeutics (BCLI) -69% after announcing topline results from Phase 3 trial evaluating NurOwn.Alterity Therapeutics (ATHE) -24%.iBio (IBIO) -20% on FQ1 earnings release.The Alkaline Water Company (WTER) -17% on FQ2 earnings release.GoodRx Holdings (GDRX) -18% tumble after
Seekingalpha · 11/17 14:01
The Daily Biotech Pulse: Setback For Alkermes, Boston Scientific's Recall, ALX-Zymeworks Oncology Collaboration
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 16)
Benzinga · 11/17 13:31
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CVAC. Analyze the recent business situations of CureVac B.V. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CVAC stock price target is 71.32 with a high estimate of 88.27 and a low estimate of 47.14.
EPS
Institutional Holdings
Institutions: 42
Institutional Holdings: 7.61M
% Owned: 4.31%
Shares Outstanding: 176.46M
TypeInstitutionsShares
Increased
0
0
New
42
7.61M
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About CVAC
CureVac AG is a Germany-based biotechnology company. The Company is engaged in the therapeutic development of messenger Ribonucleic Acid (mRNA) and RNA-based vaccines. CureVac AG focuses on developing vaccines for infectious diseases and drugs to treat cancer and rare diseases. The Company's pipeline focuses on three areas: cancer immunotherapy, prophylactic vaccines, and protein-based therapies.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of CureVac BV stock information, including NASDAQ:CVAC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CVAC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CVAC stock methods without spending real money on the virtual paper trading platform.